Translucent
FDA Releases Second Batch of Complete Response Letters, Moves to Real-Time Public Disclosure
FDA; Complete Response Letters; CRLs; real-time publishing; drug approvals; transparency; regulatory disclosure
Conflicts of Interest Among Federal Vaccine Advisors at Historic Lows Through 2024
conflicts of interest; vaccine advisory committees; ACIP; VRBPAC; CDC; FDA; transparency; Robert F. Kennedy Jr.; JAMA study
Untangling Sarepta’s Gene Therapy Fallout and Trust Deficit
Sarepta Therapeutics; gene therapy; Elevidys; Duchenne muscular dystrophy; limb-girdle muscular dystrophy; patient deaths; FDA; AAVrh74 vector; regulatory action; clinical holds; transparency
Science-Led Storytelling Takes Center Stage in Pharma Communications (June 2025)
pharmaceutical communications; science-led storytelling; pharma marketing; patient engagement; trust and transparency; Cheryl Lubbert; Reverba Global
Vanda Escalates Vendetta Against FDA, Blasts Bureaucrats for Delaying Stomach Drug
United States Food and Drug Administration, Vanda, United States Food and Drug Administration, Gastroparesis, Translucent
Congressional Healthcare Reform Priorities Under Trump’s Second Term
ACA repeal, Medicaid block grants, price transparency, Medicare Advantage, drug pricing, value-based care
Pharmaceutical CEOs Emphasize Transparency to Counter Anti-Vaccine Sentiment in the US
Anti-vaccine movement, Transparency, GSK, Sanofi, Vaccine hesitancy, Public health
Congress Eyes Major PBM Reforms in Year-End Spending Bill
Pharmacy Benefit Managers (PBMs), PBM reforms, healthcare costs, year-end spending bill, Congress, bipartisan legislation, transparency, drug prices.
FDA Enhances Transparency in Drug Review Process with Revised Document Structure
FDA, drug review process, transparency, document structure, regulatory oversight
Pharmaceutical Industry’s Public Image Deteriorates Post-Pandemic Era
Pharmaceutical industry, reputation, pandemic, public opinion, COVID-19, vaccine development, drug pricing, transparency.